A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma

被引：14

作者：

Enomoto, Yasunori ^{[1
]}

Kasai, Takahiko ^{[1
]}

Takeda, Maiko ^{[1
]}

Takano, Masato ^{[1
]}

Morita, Kouhei ^{[1
]}

Kadota, Eiji ^{[3
]}

Iizuka, Norishige ^{[3
]}

Maruyama, Hiroshi ^{[4
]}

Haratake, Joji ^{[5
]}

Kojima, Yu ^{[2
]}

Ikeda, Naoya ^{[2
]}

Nonomura, Akitaka ^{[1
]}

机构：

[1] Nara Med Univ, Dept Diagnost Pathol, Sch Med, Kashihara, Nara 6348521, Japan

[2] Nara Prefectural Mimuro Hosp, Dept Surg, Nara, Japan

[3] Kishiwada City Hosp, Dept Lab Med & Pathol, Osaka, Japan

[4] Hoshigaoka Koseinenkin Hosp, Dept Pathol, Osaka, Japan

[5] Saiseikai Yahata Gen Hosp, Dept Diagnost Pathol, Fukuoka, Japan

来源：

PATHOLOGY INTERNATIONAL | 2012年 / 62卷 / 04期

关键词：

epidermal growth factor receptor; FISH; gene copy number gain; immunohistochemistry; malignant mesothelioma; PROTEIN EXPRESSION; LUNG-CANCER; PHASE-II; EGFR; GENE; MUTATIONS; GEFITINIB; PROGNOSIS;

D O I：

10.1111/j.1440-1827.2011.02778.x

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

An evaluation of epidermal growth factor receptor (EGFR) phenotypic expression in malignant pleural and peritoneal mesothelioma was undertaken, using immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) analysis. Thirty-eight malignant mesothelioma (MM) specimens were subjected to IHC staining and FISH to evaluate the expression of EGFR protein and gene status. Overall positive IHC reaction was detected in 20/38 (53%) cases, in 11/22 (50%) pleural MM, and in 9/16 (56%) peritoneal MM. Our study confirmed that EGFR membranous expression is a common feature in MM, but not in benign mesothelial lesion. Thirty-seven cases did not show a gene copy number gain. Only one case showed a copy number gain. The protein overexpression of EGFR was not related to a gene copy number gain.

引用

页码：226 / 231

页数：6

共 26 条

[1] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[2] The pathogenesis of mesothelioma [J].

Carbone, M ;

Kratzke, RA ;

Testa, JR .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :2-17

[3] MALIGNANT PLEURAL MESOTHELIOMA AND EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) - RELATIONSHIP OF EGF-R WITH HISTOLOGY AND SURVIVAL USING FIXED PARAFFIN EMBEDDED TISSUE AND THE F4, MONOCLONAL-ANTIBODY [J].

DAZZI, H ;

HASLETON, PS ;

THATCHER, N ;

WILKES, S ;

SWINDELL, R ;

CHATTERJEE, AK .

BRITISH JOURNAL OF CANCER, 1990, 61 (06) :924-926

[4] EGFR overexpression in malignant pleural mesothelioma - An immunohistochemical and molecular study with clinico-pathological correlations [J].

Destro, A ;

Ceresoli, GL ;

Falleni, M ;

Zucali, PA ;

Morenghi, E ;

Bianchi, P ;

Pellegrini, C ;

Cordani, N ;

Vaira, V ;

Alloisio, M ;

Rizzi, A ;

Bosari, S ;

Roncalli, M .

LUNG CANCER, 2006, 51 (02) :207-215

[5] EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma [J].

Edwards, J. G. ;

Swinson, D. E. B. ;

Jones, J. L. ;

Waller, D. A. ;

O'Byrne, K. J. .

LUNG CANCER, 2006, 54 (03) :399-407

[6] Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma [J].

Foster, Jason M. ;

Radhakrishna, Uppala ;

Govindarajan, Venkatesh ;

Carreau, Joseph H. ;

Gatalica, Zoran ;

Sharma, Poonam ;

Nath, Swapan K. ;

Loggie, Brian W. .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2010, 8

[7] Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma [J].

Foster, Jason M. ;

Gatalica, Zoran ;

Lilleberg, Stan ;

Haynatzki, Gleb ;

Loggie, Brian W. .

ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (01) :152-158

[8] Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study [J].

Garland, Linda L. ;

Rankin, Cathryn ;

Gandara, David R. ;

Rivkin, Saul E. ;

Scott, Katherine M. ;

Nagle, Raymond B. ;

Klein-Szanto, Andres J. P. ;

Testa, Joseph R. ;

Altomare, Deborah A. ;

Borden, Ernest C. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) :2406-2413

[9] SV40 associated miRNAs are not detectable in mesotheliomas [J].

Gee, G. V. ;

Stanifer, M. L. ;

Christensen, B. C. ;

Atwood, W. J. ;

Ugolini, D. ;

Bonassi, S. ;

Resnick, M. B. ;

Nelson, H. H. ;

Marsit, C. J. ;

Kelsey, K. T. .

BRITISH JOURNAL OF CANCER, 2010, 103 (06) :885-888

[10] Gefitinib in patients with malignant mesothelioma: A phase II study by the cancer and leukemia group B [J].

Govindan, R ;

Kratzke, RA ;

Herndon, JE ;

Niehans, GA ;

Vollmer, R ;

Watson, D ;

Green, MR ;

Kindler, HL .

CLINICAL CANCER RESEARCH, 2005, 11 (06) :2300-2304

← 1 2 3 →